A Markov decision analysis of allogeneic hematopoietic cell transplantation versus chemotherapy in patients with acute myeloid leukemia in first remission-Reference-Cited by-同舟云学术

A Markov decision analysis of allogeneic hematopoietic cell transplantation versus chemotherapy in patients with acute myeloid leukemia in first remission

Published:2011-02-17 Issue:7 Volume:117 Page:2113-2120
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Kurosawa Saiko¹,Yamaguchi Takuhiro²,Miyawaki Shuichi³,Uchida Naoyuki⁴,Kanamori Heiwa⁵,Usuki Kensuke⁶,Yamashita Takuya⁷,Watanabe Masato⁸,Yakushiji Kazuaki⁹,Yano Shingo¹⁰,Nawa Yuichiro¹¹,Taguchi Jun¹²,Takeuchi Jin¹³,Tomiyama Junji¹⁴,Nakamura Yuko¹⁵,Miura Ikuo¹⁶,Kanda Yoshinobu¹⁷,Takaue Yoichi¹,Fukuda Takahiro¹

Affiliation:

1. Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan;

2. Clinical Data Management Division, University of Tokyo, Tokyo, Japan;

3. Metropolitan Ohtsuka Hospital, Tokyo, Japan;

4. Toranomon Hospital, Tokyo, Japan;

5. Kanagawa Cancer Center, Kanagawa, Japan;

6. NTT Kanto Medical Center, Tokyo, Japan;

7. Metropolitan Komagome Hospital, Tokyo, Japan;

8. Yamada Hospital, Gifu, Japan;

9. Kurume University, Fukuoka, Japan;

10. Jikei University, Tokyo, Japan;

11. Ehime Prefectural Central Hospital, Ehime, Japan;

12. Nagasaki University, Nagasaki, Japan;

13. Nihon University, Tokyo, Japan;

14. Metropolitan Bokutoh Hospital, Tokyo, Japan;

15. Dokkyo Medical University, Tochigi, Japan;

16. St Marianna University School of Medicine Hospital, Kanagawa, Japan; and

17. Saitama Medical Center, Jichi Medical University, Saitama, Japan

Abstract

Abstract Various prospective trials have been performed to assess the roles of allogeneic hematopoietic cell transplantation (allo-HCT) and chemotherapy in patients with acute myeloid leukemia (AML) in first complete remission (CR1). However, the results have not always been consistent, and there has been a limited evaluation of quality of life (QOL) in these postremission strategies. We performed a Markov decision analysis that enabled us to compare survival outcomes with a QOL evaluation using a database of 2029 adult AML patients who achieved CR1. The Markov decision model compared 2 strategies: allo-HCT or chemotherapy in CR1. Patients who had intermediate- or unfavorable-risk AML had a longer life expectancy when they received allo-HCT in CR1 than patients treated with chemotherapy alone. Likewise, patients who had a suitable related donor who received allo-HCT in CR1 had a longer life expectancy. The life expectancy was shortened to a greater degree by adjustment for QOL in the allo-HCT group. Nevertheless, QOL-adjusted life expectancies in most of the subgroups remained longer in the allo-HCT group than in the chemotherapy group. Our results showed that older patients with a related donor and younger patients with unfavorable cytogenetics benefited the most from allo-HCT in CR1.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/117/7/2113/1492638/zh800711002113.pdf

Reference24 articles.

1. Acute myeloid leukemia.;Lowenberg;N Engl J Med,1999

2. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study.;Slovak;Blood,2000

3. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial.;Suciu;Blood,2003

4. Early allogeneic stem-cell transplantation for young adults with acute myeloblastic leukemia in first complete remission: an intent-to-treat long-term analysis of the BGMT experience.;Jourdan;J Clin Oncol,2005

5. Long-term results of the MRC AML10 trial.;Burnett;Clin Adv Hematol Oncol,2006

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Markov analysis of azacitidine and venetoclax vs induction chemotherapy for medically fit patients with AML;Blood Advances;2024-02-13

2. The measurement and use of patient-reported outcomes in the setting of hematopoietic stem cell transplantation;Japanese Journal of Transplantation and Cellular Therapy;2023

3. Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain;ClinicoEconomics and Outcomes Research;2021-04

4. Outcomes of Allogeneic Stem Cell Transplant for Elderly Patients with Hematologic Malignancies;Biology of Blood and Marrow Transplantation;2020-04

5. Decision-analytic modeling as a tool for selecting optimal therapy incorporating hematopoietic stem cell transplantation in patients with hematological malignancy;Bone Marrow Transplantation;2020-01-13